T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Purpose
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Conditions
- Anatomic Stage IA Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage IIA Breast Cancer AJCC v8
- Anatomic Stage IIB Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IIIA Breast Cancer AJCC v8
- Anatomic Stage IIIB Breast Cancer AJCC v8
- Anatomic Stage IIIC Breast Cancer AJCC v8
- HER2 Positive Breast Carcinoma
- Invasive Breast Carcinoma
- Multifocal Breast Carcinoma
- Prognostic Stage I Breast Cancer AJCC v8
- Prognostic Stage IA Breast Cancer AJCC v8
- Prognostic Stage IB Breast Cancer AJCC v8
- Prognostic Stage II Breast Cancer AJCC v8
- Prognostic Stage IIA Breast Cancer AJCC v8
- Prognostic Stage IIB Breast Cancer AJCC v8
- Prognostic Stage III Breast Cancer AJCC v8
- Prognostic Stage IIIA Breast Cancer AJCC v8
- Prognostic Stage IIIB Breast Cancer AJCC v8
- Prognostic Stage IIIC Breast Cancer AJCC v8
- Synchronous Bilateral Breast Carcinoma
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- HER2-positive status will be based on pretreatment biopsy material and defined as an immunohistochemistry (IHC) score of 3+ and/or positive by in situ hybridization (ISH) according to current American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines. Central testing is not required * Known hormone receptor (HR) status as defined by ASCO/CAP guidelines (based on pretreatment biopsy material). Hormone receptor positive status can be determined by either known positive estrogen receptor (ER) or known positive progesterone receptor (PR) status; hormone receptor negative status must be determined by both known negative ER and known negative PR - Patients with clinical stage T1-4, N0-3 disease at presentation and residual invasive disease postoperatively as defined above are eligible. (Note: Patients with T1a/bN0 tumors are not eligible at initial breast cancer diagnosis are not eligible) - Patients with residual HR-negative, HER2 positive (+) disease in the breast and/or lymph nodes per the surgical pathology report are eligible; however, patients with HR+ HER2+ cancers must have node-positive residual disease per the surgical pathology report in order to qualify for the study. The presence of residual invasive disease in the breast is not mandatory for these patients - Patients with weakly ER-positive (1-10%) breast cancer (based on the pretreatment core biopsy) are eligible even if they have node-negative disease per the surgical pathology report - The residual disease tissue (breast and/or lymph nodes) is not required to be HER2-positive, as eligibility for NCI-2020-03770 (A011801) is based on a positive HER2 status at the time of the initial breast cancer diagnosis * Note: The presence of micrometastases in lymph nodes after preoperative therapy counts as residual disease, whereas the presence of isolated tumor cells does not - Patients with synchronous bilateral invasive disease are eligible provided both lesions were confirmed to be HER2-positive, and at least one of the lesions meets the criteria outlined above. Multifocal disease is allowed, as long as the largest biopsied breast tumor was HER2-positive - Patients must have received neoadjuvant chemotherapy with one of the following regimens: docetaxel/trastuzumab/pertuzumab (THP), paclitaxel/methotrexate/cisplatin (TMP), doxorubicin/cyclophosphamide/paclitaxel/trastuzumab/pertuzumab (AC-TH(P)); docetaxel/carboplatin/trastuzumab/pertuzumab (TCH(P)); fluorouracil/doxorubicin/cyclophosphamide-docetaxel/trastuzumab/pertuzumab (FAC-TH(P)), or fluorouracil/epirubicin/cyclophosphamide-docetaxel/trastuzumab/pertuzumab (FEC-TH(P)). Note: apart from TCHP, where T is docetaxel, treatment with docetaxel or paclitaxel is acceptable - Prior receipt of T-DM1 in the neoadjuvant setting is not allowed. - Prior treatment must have consisted of >= 6 cycles of chemotherapy and HER2-directed therapy, with a total duration of >= 12 weeks, including at least 9 weeks of preoperative taxane and trastuzumab with or without pertuzumab (or Food and Drug Administration [FDA]-approved biosimilars). Patients who have received at least 9 weeks of preoperative taxane, pertuzumab and margetuximab are also eligible if they received >= 6 cycles of systemic therapy prior to enrollment. Note: Patients who complete at least nine of a planned twelve doses of weekly paclitaxel, or three of a planned four doses of docetaxel, but discontinue prematurely due to toxicity are eligible. Patients receiving dose-dense chemotherapy regimens are also eligible. Prior use of nab-paclitaxel (Abraxane) instead of paclitaxel or docetaxel is permitted. Prior use of subcutaneous trastuzumab (Hylecta) and subcutaneous trastuzumab and pertuzumab (Phesgo) is also allowed. - Patients who received neoadjuvant systemic therapy which included experimental HER2-targeted therapy/therapies are potentially eligible, as long as the investigational agent was not a HER2-targeted antibody-drug conjugate (e.g. T-DM1, DS-8201a [trastuzumab deruxtecan]) or a HER2 targeted tyrosine kinase inhibitor (TKI) (e.g. tucatinib, lapatinib, neratinib). - Patients may have received =< 1 cycles of T-DM1 in the adjuvant setting. Note: These patients will be randomized to receive a further 14 cycles of T-DM1 and tucatinib/placebo as tolerated. The most recent cycle of T-DM1 should have been administered =< 5 weeks prior to registration * Note: Both of the following two criteria need to be met for the patient to be eligible for this study - An interval of no more than 12 weeks between the completion date of the last definitive treatment (e.g. postoperative chemotherapy or radiation, or if neither given, breast surgical date) and the date of registration. Concurrent radiation therapy is permitted while receiving study treatment - Patients must be registered on study within =< 180 days of the date of the most recent definitive breast cancer surgery (not including reconstructive surgery) - All systemic chemotherapy should have been completed preoperatively unless participating in EA1181 (CompassHER2 pathologic complete response [pCR]) or the BIG DECRESCENDO Trial (which is very similar to CompassHER2 pCR in terms of study design, drugs, and eligibility). However, patients who received 4 cycles of neoadjuvant THP off study can receive a further 2-4 cycles of chemotherapy postoperatively to meet eligibility for A011801. Patients who participated in EA1181 or MA41 and proceeded to surgery immediately after the de-escalated trial regimen must receive postoperative chemotherapy to complete a total of >= 6 cycles of systemic treatment prior to enrollment on A011801, as outlined above (e.g. 4 cycles pre-operatively, and 2 cycles post-operatively). The postoperative chemotherapy regimen prescribed is at the discretion of the treating oncologist (i.e. 2-4 cycles AC or THP, other). Continuation of trastuzumab + pertuzumab (HP) pre- or post-operatively as maintenance therapy (while awaiting a surgical date or an official pathology report) is allowed for all study participants - Toxicities related to prior systemic treatment should have resolved or be at baseline, apart from alopecia and peripheral neuropathy =< grade 1 - Adequate excision: surgical removal of all clinically evident disease in the breast and lymph nodes as follows: - Breast surgery: total mastectomy with no gross residual disease at the margin of resection, or breast-conserving surgery with histologically negative margins of excision - For patients who undergo breast-conserving surgery, the margins of the resected specimen must be histologically free of invasive tumor and ductal carcinoma in situ (DCIS) as determined by the local pathologist. If pathologic examination demonstrates tumor at the line of resection, additional operative procedures may be performed to obtain clear margins. If tumor is still present at the resected margin after re-excision(s), the patient must undergo total mastectomy to be eligible. Patients with margins positive for classic lobular carcinoma in situ (LCIS) are eligible without additional resection - Lymph node surgery ** The axilla needs to be evaluated with either sentinel node biopsy or axillary lymph node dissection. If patients have a sentinel lymph node biopsy and sentinel nodes are negative, no further axillary treatment is necessary. If patients have isolated tumor cells (ITCs) in the setting of residual breast disease, at least one of the following is required: axillary lymph node dissection (ALND) or planned nodal irradiation. If patients have micro- or macro-metastatic nodal disease, ALND and planned nodal irradiation are required. Of note, co-enrollment on Alliance A011202 is not allowed - Eastern Cooperative Oncology Group (ECOG) performance status 0-1 - Absolute neutrophil count (ANC) >= 1,000/mm^3 - Hemoglobin >= 8 g/dL (Note: packed red blood cells [PRBC] transfusion is not permitted to achieve eligibility) - Platelet count >= 100,000/mm^3 - Creatinine =< 1.5 x upper limit of normal (ULN) - Total bilirubin =< 1.0 x upper limit of normal (ULN) or direct bilirubin within the institutional normal range for patients with Gilbert's syndrome - Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) - Screening left ventricular ejection fraction (LVEF) >= 50% on echocardiogram (ECHO) or multiple-gated acquisition (MUGA) after receiving neoadjuvant chemotherapy and no decrease in LVEF by more than 15% absolute percentage points from the pre-chemotherapy LVEF. Or, if pre-chemotherapy LVEF was not assessed, the screening LVEF must be >= 55% after completion of neoadjuvant chemotherapy. Note: LVEF assessment may be repeated once up to 3 weeks following the initial screening assessment to assess eligibility
Exclusion Criteria
- No adjuvant treatment with any anti-cancer investigational drug within 28 days prior to registration - Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative serum pregnancy test done =< 7 days prior to registration is required - Patients with known active and/or untreated hepatitis B or hepatitis C or chronic liver disease are ineligible. Patients with a diagnosis of hepatitis B or C that has been treated and cleared and normal liver function are eligible to participate in the study if the other eligibility parameters are met - Stage IV (metastatic) breast cancer - History of any prior (ipsi- or contralateral) invasive breast cancer within 3 years of registration - Patients with ER+ HER2+ residual invasive disease that is lymph node-negative per the surgical pathology report - Evidence of recurrent disease following preoperative therapy and surgery - Patients for whom radiotherapy would be recommended for breast cancer treatment but for whom it is contraindicated because of medical reasons (e.g., connective tissue disorder or prior ipsilateral breast radiation) - History of exposure to the following cumulative doses of anthracyclines: doxorubicin > 240 mg/m^2; epirubicin or liposomal doxorubicin-hydrochloride (Myocet) > 480 mg/m^2. For other anthracyclines, exposure equivalent to doxorubicin > 240 mg/m^2 - Cardiopulmonary dysfunction as defined by any of the following: - History of National Cancer Institute (NCI) CTCAE version (v) 5.0 grade >= 3 symptomatic congestive heart failure (CHF) or New York Heart Association (NYHA) criteria class >= II - Angina pectoris requiring anti-anginal medication, serious cardiac arrhythmia not controlled by adequate medication, severe conduction abnormality, or clinically significant valvular disease - High-risk uncontrolled arrhythmias: i.e., atrial tachycardia with a heart rate > 100/min at rest, significant ventricular arrhythmia (ventricular tachycardia) or higher-grade atrioventricular block (AV)-block (second degree AV-block type 2 [Mobitz 2] or third degree AV-block) - Significant symptoms (grade >= 2) relating to left ventricular dysfunction, cardiac arrhythmia, or cardiac ischemia while or since receiving preoperative therapy - History of a decrease in left ventricular ejection fraction (LVEF) to < 40% with prior trastuzumab treatment (e.g., during preoperative therapy) - Uncontrolled hypertension (systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 100 mmHg) - Current severe, uncontrolled systemic disease - Major surgical procedure unrelated to breast cancer or significant traumatic injury within 28 days prior to registration or anticipation of the need for major surgery during the course of study treatment - History of intolerance, including grade 3 to 4 infusion reaction or hypersensitivity to trastuzumab or murine proteins or any components of the product - Peripheral neuropathy of any etiology that exceeds grade 1 - Assessment by the investigator as being unable or unwilling to comply with the requirements of the protocol - Use of a strong CYP3A4 or CYP2C8 inhibitor within 2 weeks, or use of a strong CYP3A4 or CYP2C8 inducer within 5 days prior to registration is prohibited. - Please note that use of sensitive CYP3A substrates should be avoided two weeks before registration and during study treatment. Additionally, CYP3A4 or CYP2C8 inducers are prohibited as concomitant medications within 5 days following discontinuation of tucatinib treatment. Patients who require medications that are known to be sensitive substrates of CYP3A4 with a narrow therapeutic window should be excluded.
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Active Comparator Arm I (trastuzumab emtansine, placebo) |
Patients receive T-DM1 IV over 30-90 minutes on day 1 and placebo PO BID on days 1-21. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity. |
|
Experimental Arm II (trastuzumab emtansine, tucatinib) |
Patients receive T-DM1 IV over 30-90 minutes on day 1 and tucatinib PO BID on days 1-21. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity. |
|
Recruiting Locations
Birmingham, Alabama 35233
Fairhope, Alabama 36532
Site Public Contact
251-435-4584
Mobile, Alabama 36607
Site Public Contact
251-435-3942
Fairbanks, Alaska 99701
Gilbert, Arizona 85234
Site Public Contact
602-747-9738
Kingman, Arizona 86401
Phoenix, Arizona 85006
Jonesboro, Arkansas 72401
Little Rock, Arkansas 72205
Site Public Contact
501-686-8274
Auburn, California 95602
Berkeley, California 94702
Berkeley, California 94704
Beverly Hills, California 90211
Carmichael, California 95608
Carmichael, California 95608
Clovis, California 93611
Site Public Contact
559-387-1827
Costa Mesa, California 92627
Site Public Contact
877-827-8839
Duarte, California 91010
Dublin, California 94568
Site Public Contact
877-642-4691
Elk Grove, California 95758
Fremont, California 94538
Fremont, California 94538
Fremont, California 94538
Site Public Contact
510-745-6433
Fresno, California 93720
Fullerton, California 92835
Site Public Contact
714-446-5642
Irvine, California 92612
Irvine, California 92618
Site Public Contact
877-467-3411
Los Angeles, California 90020
Site Public Contact
213-388-0908
Los Angeles, California 90033
Los Angeles, California 90033
Site Public Contact
323-865-0451
Los Angeles, California 90048
Site Public Contact
310-423-8965
Modesto, California 95355
Modesto, California 95356
Mountain View, California 94040
Newport Beach, California 92660
Site Public Contact
877-467-3411
Oakland, California 94611
Orange, California 92868
Site Public Contact
714-734-6220
Orange, California 92868
Palm Springs, California 92262
Site Public Contact
760-416-4730
Palo Alto, California 94301
Palo Alto, California 94304
Pasadena, California 91105
Site Public Contact
626-535-2420
Rancho Mirage, California 92270
Site Public Contact
760-834-3798
Rocklin, California 95765
Roseville, California 95661
Roseville, California 95661
Sacramento, California 95814
Sacramento, California 95816
Sacramento, California 95816
Sacramento, California 95823
Saint Helena, California 94574
Site Public Contact
707-967-3698
Salinas, California 93901
San Francisco, California 94110
San Francisco, California 94115
San Francisco, California 94115
San Francisco, California 94158
San Jose, California 95119
San Jose, California 95124
San Leandro, California 94577
San Mateo, California 94402
San Rafael, California 94903
Santa Clara, California 95051
Santa Cruz, California 95065
Santa Rosa, California 95403
Santa Rosa, California 95403
Site Public Contact
707-521-3830
Santa Rosa, California 95403
Santa Rosa, California 95405
Site Public Contact
707-521-3830
South Pasadena, California 91030
South San Francisco, California 94080
Sunnyvale, California 94086
Torrance, California 90503
Site Public Contact
877-467-3411
Torrance, California 90505
Upland, California 91786
Vallejo, California 94589
Vallejo, California 94589
Walnut Creek, California 94596
Walnut Creek, California 94598
Woodland, California 95695
Aurora, Colorado 80012
Aurora, Colorado 80045
Site Public Contact
720-848-0650
Boulder, Colorado 80304
Centennial, Colorado 80112
Colorado Springs, Colorado 80907
Colorado Springs, Colorado 80909
Site Public Contact
719-365-2406
Colorado Springs, Colorado 80920
Site Public Contact
719-364-6700
Denver, Colorado 80206
Denver, Colorado 80218
Denver, Colorado 80218
Denver, Colorado 80220
Edwards, Colorado 81632
Site Public Contact
970-569-7429
Fort Collins, Colorado 80524
Site Public Contact
970-297-6150
Fort Collins, Colorado 80528
Golden, Colorado 80401
Grand Junction, Colorado 81505
Greeley, Colorado 80631
Greeley, Colorado 80631
Highlands Ranch, Colorado 80129
Site Public Contact
720-848-0650
Littleton, Colorado 80120
Lone Tree, Colorado 80124
Lone Tree, Colorado 80124
Longmont, Colorado 80501
Loveland, Colorado 80538
Site Public Contact
970-203-7083
Loveland, Colorado 80539
Bridgeport, Connecticut 06606
Site Public Contact
860-972-4700
Danbury, Connecticut 06810
Site Public Contact
203-739-8074
Fairfield, Connecticut 06824
Glastonbury, Connecticut 06033
Hartford, Connecticut 06102
Site Public Contact
860-545-5363
Hartford, Connecticut 06105
Meriden, Connecticut 06451
Site Public Contact
866-662-5678
New Britain, Connecticut 06050
Site Public Contact
860-224-5660
New Haven, Connecticut 06520
North Haven, Connecticut 06473
Norwalk, Connecticut 06856
Torrington, Connecticut 06790
Trumbull, Connecticut 06611
Waterbury, Connecticut 06708
Waterford, Connecticut 06385
Frankford, Delaware 19945
Newark, Delaware 19713
Newark, Delaware 19713
Rehoboth Beach, Delaware 19971
Washington, District of Columbia 20002
Site Public Contact
301-548-5743
Washington, District of Columbia 20007
Site Public Contact
202-444-2223
Washington, District of Columbia 20010
Site Public Contact
202-877-8839
Washington, District of Columbia 20016
Altamonte Springs, Florida 32701
Site Public Contact
407-303-2200
Aventura, Florida 33180
Aventura, Florida 33180
Site Public Contact
954-461-2180
Boca Raton, Florida 33486
Site Public Contact
561-955-4800
Clearwater, Florida 33756
Site Public Contact
855-314-8646
Coral Gables, Florida 33146
Site Public Contact
305-243-2647
Deerfield Beach, Florida 33442
Site Public Contact
305-243-2647
Fort Lauderdale, Florida 33308
Miami Beach, Florida 33140
Miami, Florida 33136
Site Public Contact
305-243-2647
Miami, Florida 33176
Site Public Contact
305-243-2647
Orlando, Florida 32803
Orlando, Florida 32806
Pensacola, Florida 32504
Plantation, Florida 33324
Site Public Contact
305-243-2647
Safety Harbor, Florida 34695
Saint Petersburg, Florida 33705
Tampa, Florida 33606
Tampa, Florida 33607
Albany, Georgia 31701
Athens, Georgia 30607
Atlanta, Georgia 30303
Site Public Contact
404-489-9164
Atlanta, Georgia 30308
Site Public Contact
888-946-7447
Atlanta, Georgia 30322
Site Public Contact
404-778-1868
Atlanta, Georgia 30342
Site Public Contact
404-851-7115
Atlanta, Georgia 30342
Augusta, Georgia 30901
Site Public Contact
706-821-2944
Augusta, Georgia 30909
Site Public Contact
706-736-1830
Decatur, Georgia 30033
Site Public Contact
404-321-6111
Duluth, Georgia 30096
Lawrenceville, Georgia 30046
Newnan, Georgia 30265
Site Public Contact
770-400-6629
Savannah, Georgia 31404
Savannah, Georgia 31405
'Aiea, Hawaii 96701
'Aiea, Hawaii 96701
Site Public Contact
808-486-6000
Honolulu, Hawaii 96813
Honolulu, Hawaii 96813
Site Public Contact
808-532-0315
Honolulu, Hawaii 96813
Site Public Contact
808-545-8548
Honolulu, Hawaii 96813
Site Public Contact
808-522-4333
Honolulu, Hawaii 96817
Site Public Contact
808-531-8521
Honolulu, Hawaii 96819
Honolulu, Hawaii 96826
Site Public Contact
808-983-6090
Boise, Idaho 83706
Caldwell, Idaho 83605
Coeur d'Alene, Idaho 83814
Nampa, Idaho 83687
Post Falls, Idaho 83854
Sandpoint, Idaho 83864
Arlington Heights, Illinois 60005
Site Public Contact
847-618-4968
Aurora, Illinois 60504
Barrington, Illinois 60010
Site Public Contact
847-842-4847
Bloomington, Illinois 61704
Carterville, Illinois 62918
Centralia, Illinois 62801
Chicago, Illinois 60608
Chicago, Illinois 60611
Chicago, Illinois 60612
Site Public Contact
312-864-5204
Chicago, Illinois 60612
Chicago, Illinois 60612
Site Public Contact
312-355-3046
Chicago, Illinois 60637
Chicago, Illinois 60657
Site Public Contact
773-296-5360
Crystal Lake, Illinois 60014
Danville, Illinois 61832
Decatur, Illinois 62526
DeKalb, Illinois 60115
Downers Grove, Illinois 60515
Effingham, Illinois 62401
Effingham, Illinois 62401
Elgin, Illinois 60123
Site Public Contact
847-429-2907
Evanston, Illinois 60201
Site Public Contact
847-570-2109
Geneva, Illinois 60134
Glenview, Illinois 60026
Site Public Contact
847-570-2109
Glenview, Illinois 60026
Site Public Contact
312-695-1102
Grayslake, Illinois 60030
Site Public Contact
312-695-1102
Harvey, Illinois 60426
Hazel Crest, Illinois 60429
Site Public Contact
708-799-9995
Highland Park, Illinois 60035
Site Public Contact
847-570-2109
Lake Forest, Illinois 60045
Libertyville, Illinois 60048
Libertyville, Illinois 60048
Mattoon, Illinois 61938
Mount Vernon, Illinois 62864
Site Public Contact
618-242-4600
New Lenox, Illinois 60451
O'Fallon, Illinois 62269
Oak Lawn, Illinois 60453-2699
Site Public Contact
800-323-8622
Orland Park, Illinois 60462
Orland Park, Illinois 60462
Park Ridge, Illinois 60068
Site Public Contact
847-384-3621
Pekin, Illinois 61554
Peoria, Illinois 61615
Rockford, Illinois 61108
Site Public Contact
815-227-2633
Rockford, Illinois 61114
Shiloh, Illinois 62269
Silvis, Illinois 61282
Springfield, Illinois 62702
Site Public Contact
217-545-7929
Springfield, Illinois 62702
Site Public Contact
800-444-7541
Springfield, Illinois 62781
Urbana, Illinois 61801
Warrenville, Illinois 60555
Yorkville, Illinois 60560
Carmel, Indiana 46032
Indianapolis, Indiana 46202
Indianapolis, Indiana 46202
Indianapolis, Indiana 46219
Indianapolis, Indiana 46227
Indianapolis, Indiana 46256
Kokomo, Indiana 46904
Michigan City, Indiana 46360
Ames, Iowa 50010
Site Public Contact
515-956-4132
Ames, Iowa 50010
Ankeny, Iowa 50023
Site Public Contact
515-282-2921
Boone, Iowa 50036
Site Public Contact
515-956-4132
Carroll, Iowa 51401
Cedar Rapids, Iowa 52402
Site Public Contact
319-297-2900
Cedar Rapids, Iowa 52403
Site Public Contact
319-365-4673
Cedar Rapids, Iowa 52403
Site Public Contact
319-363-2690
Clive, Iowa 50325
Clive, Iowa 50325
Site Public Contact
515-241-3305
Council Bluffs, Iowa 51503
Site Public Contact
712-322-4136
Council Bluffs, Iowa 51503
Creston, Iowa 50801
Davenport, Iowa 52803
Davenport, Iowa 52804
Davenport, Iowa 52807
Des Moines, Iowa 50309
Site Public Contact
515-241-6727
Des Moines, Iowa 50309
Site Public Contact
515-241-3305
Des Moines, Iowa 50314
Site Public Contact
515-282-2200
Des Moines, Iowa 50314
Des Moines, Iowa 50314
Site Public Contact
515-241-3305
Fort Dodge, Iowa 50501
Site Public Contact
515-956-4132
Fort Dodge, Iowa 50501
Site Public Contact
515-574-8302
Jefferson, Iowa 50129
Site Public Contact
515-956-4132
Marshalltown, Iowa 50158
Site Public Contact
515-956-4132
Sioux City, Iowa 51101
West Des Moines, Iowa 50266
Chanute, Kansas 66720
Dodge City, Kansas 67801
El Dorado, Kansas 67042
Garden City, Kansas 67846
Hays, Kansas 67601
Site Public Contact
785-623-5774
Independence, Kansas 67301
Kingman, Kansas 67068
Lawrence, Kansas 66044
Liberal, Kansas 67905
Newton, Kansas 67114
Olathe, Kansas 66061
Overland Park, Kansas 66209
Overland Park, Kansas 66210
Overland Park, Kansas 66211
Parsons, Kansas 67357
Pittsburg, Kansas 66762
Pittsburg, Kansas 66762
Pratt, Kansas 67124
Salina, Kansas 67401
Salina, Kansas 67401
Topeka, Kansas 66606
Site Public Contact
785-295-8000
Wellington, Kansas 67152
Westwood, Kansas 66205
Wichita, Kansas 67208
Wichita, Kansas 67214
Wichita, Kansas 67214
Winfield, Kansas 67156
Ashland, Kentucky 41101
Site Public Contact
606-327-6499
Corbin, Kentucky 40701
Site Public Contact
859-523-1934
Lexington, Kentucky 40503
Site Public Contact
859-260-6425
Lexington, Kentucky 40509
Lexington, Kentucky 40536
Site Public Contact
859-257-3379
Louisville, Kentucky 40207
New Orleans, Louisiana 70112
Augusta, Maine 04330
Site Public Contact
207-626-4855
Biddeford, Maine 04005
Brewer, Maine 04412
Site Public Contact
800-987-3005
Sanford, Maine 04073
Scarborough, Maine 04074
South Portland, Maine 04106
Topsham, Maine 04086
York, Maine 03909
Site Public Contact
207-351-3777
Annapolis, Maryland 21401
Baltimore, Maryland 21204
Site Public Contact
443-849-3706
Baltimore, Maryland 21215
Baltimore, Maryland 21237
Site Public Contact
443-777-7364
Baltimore, Maryland 21239
Baltimore, Maryland 21244
Site Public Contact
301-816-7218
Baltimore, Maryland 21287
Bel Air, Maryland 21014
Site Public Contact
443-643-3010
Bethesda, Maryland 20889-5600
Site Public Contact
301-319-2100
Cumberland, Maryland 21502
Site Public Contact
240-964-1400
Easton, Maryland 21601
Gaithersburg, Maryland 20879
Site Public Contact
301-816-7218
Kensington, Maryland 20895
Site Public Contact
301-816-7218
Largo, Maryland 20774
Site Public Contact
301-816-7446
Lutherville, Maryland 21093
Site Public Contact
410-847-3000
Olney, Maryland 20832
Site Public Contact
855-546-1944
Westminster, Maryland 21157
Site Public Contact
410-871-6400
Beverly, Massachusetts 01915
Site Public Contact
978-922-3000
Boston, Massachusetts 02111
Boston, Massachusetts 02118
Site Public Contact
617-638-8265
Boston, Massachusetts 02215
Site Public Contact
617-667-9925
Boston, Massachusetts 02215
Site Public Contact
877-442-3324
Burlington, Massachusetts 01805
Foxboro, Massachusetts 02035
Site Public Contact
877-338-7425
Gloucester, Massachusetts 01930
Site Public Contact
978-283-4000
Hyannis, Massachusetts 02601
Site Public Contact
508-862-5799
Lowell, Massachusetts 01854
Milford, Massachusetts 01757
Site Public Contact
877-332-4294
Peabody, Massachusetts 01960
South Weymouth, Massachusetts 02190
Site Public Contact
781-624-5000
Winchester, Massachusetts 01890
Ann Arbor, Michigan 48106
Ann Arbor, Michigan 48109
Site Public Contact
800-865-1125
Battle Creek, Michigan 49017
Brighton, Michigan 48114
Brighton, Michigan 48114
Canton, Michigan 48188
Canton, Michigan 48188
Chelsea, Michigan 48118
Chelsea, Michigan 48118
Clarkston, Michigan 48346
Clarkston, Michigan 48346
Dearborn, Michigan 48124
Site Public Contact
248-551-7695
Detroit, Michigan 48201
Detroit, Michigan 48236
Farmington Hills, Michigan 48334
Farmington Hills, Michigan 48336
Site Public Contact
248-551-7695
Flint, Michigan 48503
Flint, Michigan 48503
Flint, Michigan 48503
Flint, Michigan 48503
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49009
Lansing, Michigan 48912
Livonia, Michigan 48154
Muskegon, Michigan 49444
Niles, Michigan 49120
Site Public Contact
616-391-1230
Norton Shores, Michigan 49444
Novi, Michigan 48374
Pontiac, Michigan 48341
Pontiac, Michigan 48341
Pontiac, Michigan 48341
Reed City, Michigan 49677
Royal Oak, Michigan 48073
Site Public Contact
248-551-7695
Saginaw, Michigan 48601
Saginaw, Michigan 48604
Saint Joseph, Michigan 49085
Saint Joseph, Michigan 49085
Southfield, Michigan 48075
Tawas City, Michigan 48764
Traverse City, Michigan 49684
Troy, Michigan 48085
Site Public Contact
248-551-7695
West Branch, Michigan 48661
Wyoming, Michigan 49519
Ypsilanti, Michigan 48106
Ypsilanti, Michigan 48197
Bemidji, Minnesota 56601
Burnsville, Minnesota 55337
Coon Rapids, Minnesota 55433
Deer River, Minnesota 56636
Duluth, Minnesota 55805
Duluth, Minnesota 55805
Edina, Minnesota 55435
Hibbing, Minnesota 55746
Site Public Contact
218-786-3308
Maplewood, Minnesota 55109
Minneapolis, Minnesota 55407
Minneapolis, Minnesota 55415
Robbinsdale, Minnesota 55422
Rochester, Minnesota 55905
Site Public Contact
855-776-0015
Saint Cloud, Minnesota 56303
Saint Louis Park, Minnesota 55416
Saint Paul, Minnesota 55101
Saint Paul, Minnesota 55102
Sandstone, Minnesota 55072
Shakopee, Minnesota 55379
Virginia, Minnesota 55792
Columbus, Mississippi 39705
Grenada, Mississippi 38901
New Albany, Mississippi 38652
Oxford, Mississippi 38655
Southhaven, Mississippi 38671
Ballwin, Missouri 63011
Site Public Contact
314-251-7058
Cape Girardeau, Missouri 63703
Chesterfield, Missouri 63017
Site Public Contact
314-205-6936
Columbia, Missouri 65212
Site Public Contact
573-882-7440
Creve Coeur, Missouri 63141
Farmington, Missouri 63640
Site Public Contact
314-996-5569
Independence, Missouri 64057
Kansas City, Missouri 64108
Site Public Contact
816-404-4375
Kansas City, Missouri 64111
Kansas City, Missouri 64132
Kansas City, Missouri 64154
Lee's Summit, Missouri 64064
Lee's Summit, Missouri 64086
North Kansas City, Missouri 64116
Saint Louis, Missouri 63110
Saint Louis, Missouri 63128
Saint Louis, Missouri 63129
Saint Louis, Missouri 63131
Site Public Contact
314-996-5569
Saint Louis, Missouri 63136
Saint Louis, Missouri 63141
Site Public Contact
314-251-7066
Saint Peters, Missouri 63376
Sainte Genevieve, Missouri 63670
Site Public Contact
314-996-5569
Springfield, Missouri 65807
Site Public Contact
417-269-4520
Sullivan, Missouri 63080
Site Public Contact
314-996-5569
Sunset Hills, Missouri 63127
Site Public Contact
314-996-5569
Anaconda, Montana 59711
Billings, Montana 59101
Bozeman, Montana 59715
Great Falls, Montana 59405
Kalispell, Montana 59901
Missoula, Montana 59802
Missoula, Montana 59804
Omaha, Nebraska 68114
Site Public Contact
402-334-4773
Omaha, Nebraska 68114
Site Public Contact
402-354-5144
Omaha, Nebraska 68114
Henderson, Nevada 89052
Las Vegas, Nevada 89102
Las Vegas, Nevada 89148
Reno, Nevada 89502
Concord, New Hampshire 03301
Site Public Contact
603-224-2556
Lebanon, New Hampshire 03756
Manchester, New Hampshire 03103
Site Public Contact
800-339-6484
Berkeley Heights, New Jersey 07922
Camden, New Jersey 08103
Site Public Contact
856-325-6757
Englewood, New Jersey 07631
Site Public Contact
201-894-3456
Florham Park, New Jersey 07932
Hackensack, New Jersey 07601
Site Public Contact
551-996-2897
Hamilton, New Jersey 08690
Site Public Contact
609-631-6946
Jersey City, New Jersey 07302
Lakewood, New Jersey 08701
Livingston, New Jersey 07039
Long Branch, New Jersey 07740
Morristown, New Jersey 07960
Site Public Contact
973-971-5900
New Brunswick, New Jersey 08903
Site Public Contact
732-235-7356
Newark, New Jersey 07101
Site Public Contact
732-235-7356
Newark, New Jersey 07112
Paterson, New Jersey 07503
Somerville, New Jersey 08876
Summit, New Jersey 07902
Site Public Contact
908-522-2043
Teaneck, New Jersey 07666
Site Public Contact
201-833-6312
Toms River, New Jersey 08755
Albuquerque, New Mexico 87106
Rio Rancho, New Mexico 87124
Auburn, New York 13021
Site Public Contact
315-472-7504
Bay Shore, New York 11706
Site Public Contact
516-734-8896
Buffalo, New York 14263
East Hills, New York 11548
East Syracuse, New York 13057
Site Public Contact
315-472-7504
Glens Falls, New York 12801
Site Public Contact
518-926-6700
Jamaica, New York 11432
Site Public Contact
718-883-3000
Lake Success, New York 11042
Site Public Contact
516-734-8896
Mineola, New York 11501
Mount Kisco, New York 10549
New York, New York 10011
New York, New York 10016
New York, New York 10021
Site Public Contact
516-734-8896
New York, New York 10029
New York, New York 10032
New York, New York 10065
Site Public Contact
212-434-4460
Nyack, New York 10960
Site Public Contact
845-348-8507
Poughkeepsie, New York 12601
Site Public Contact
845-483-6483
Rochester, New York 14642
Site Public Contact
585-275-5830
Sleepy Hollow, New York 10591
Site Public Contact
914-366-1600
Stony Brook, New York 11794
Site Public Contact
800-862-2215
Syracuse, New York 13210
Site Public Contact
315-464-5476
Syracuse, New York 13215
Site Public Contact
315-472-7504
Verona, New York 13478
West Islip, New York 11795
Site Public Contact
516-326-7514
White Plains, New York 10601
Asheboro, North Carolina 27203
Site Public Contact
336-832-0836
Asheboro, North Carolina 27203
Burlington, North Carolina 27215
Cary, North Carolina 27518
Chapel Hill, North Carolina 27599
Charlotte, North Carolina 28204
Clinton, North Carolina 28328
Durham, North Carolina 27710
Site Public Contact
888-275-3853
Garner, North Carolina 27529
Gastonia, North Carolina 28054
Goldsboro, North Carolina 27534
Greensboro, North Carolina 27403
Greensboro, North Carolina 27410
Hillsborough, North Carolina 27278
Huntersville, North Carolina 28078
Jacksonville, North Carolina 28546
Kernersville, North Carolina 27284
Kinston, North Carolina 28501
Matthews, North Carolina 28105
Mooresville, North Carolina 28117
Mount Airy, North Carolina 27030
North Wilkesboro, North Carolina 28659
Pinehurst, North Carolina 28374
Raleigh, North Carolina 27607
Site Public Contact
919-785-4878
Raleigh, North Carolina 27607
Raleigh, North Carolina 27614
Reidsville, North Carolina 27320
Statesville, North Carolina 28625
Thomasville, North Carolina 27360
Winston-Salem, North Carolina 27103
Bismarck, North Dakota 58501
Fargo, North Dakota 58122
Fargo, North Dakota 58122
Belpre, Ohio 45714
Canton, Ohio 44708
Site Public Contact
888-293-4673
Canton, Ohio 44710
Centerville, Ohio 45459
Chillicothe, Ohio 45601
Cincinnati, Ohio 45219
Site Public Contact
513-585-0844
Cincinnati, Ohio 45220
Columbus, Ohio 43210
Columbus, Ohio 43213
Columbus, Ohio 43214
Columbus, Ohio 43214
Columbus, Ohio 43215
Columbus, Ohio 43219
Columbus, Ohio 43228
Dayton, Ohio 45409
Dayton, Ohio 45409
Site Public Contact
937-276-8320
Dayton, Ohio 45415
Delaware, Ohio 43015
Delaware, Ohio 43015
Dublin, Ohio 43016
Dublin, Ohio 43016
Franklin, Ohio 45005-1066
Greenville, Ohio 45331
Site Public Contact
937-569-7515
Grove City, Ohio 43123
Mansfield, Ohio 44903
Marietta, Ohio 45750
Marion, Ohio 43302
Marysville, Ohio 43040
Newark, Ohio 43055
Portsmouth, Ohio 45662
Springfield, Ohio 45504
Steubenville, Ohio 43952
Site Public Contact
888-874-7000
Sylvania, Ohio 43560
Toledo, Ohio 43623
Site Public Contact
800-444-3561
Troy, Ohio 45373
Zanesville, Ohio 43701
Lawton, Oklahoma 73505
Site Public Contact
877-231-4440
Oklahoma City, Oklahoma 73104
Oklahoma City, Oklahoma 73120
Site Public Contact
405-752-3402
Oklahoma City, Oklahoma 73142
Site Public Contact
405-773-6613
Bend, Oregon 97701
Gresham, Oregon 97030
Site Public Contact
503-413-2150
Newberg, Oregon 97132
Ontario, Oregon 97914
Oregon City, Oregon 97045
Portland, Oregon 97210
Portland, Oregon 97213
Portland, Oregon 97225
Tualatin, Oregon 97062
Site Public Contact
503-413-1742
Allentown, Pennsylvania 18103
Altoona, Pennsylvania 16601
Beaver, Pennsylvania 15009
Bethlehem, Pennsylvania 18017
Broomall, Pennsylvania 19008
Bryn Mawr, Pennsylvania 19010
Butler, Pennsylvania 16001
Carlisle, Pennsylvania 17015
Chambersburg, Pennsylvania 17201
Site Public Contact
717-217-6020
Cranberry Township, Pennsylvania 16066
Danville, Pennsylvania 17822
Drexel Hill, Pennsylvania 19026
Ephrata, Pennsylvania 17522
Site Public Contact
717-721-4840
Erie, Pennsylvania 16505
Farrell, Pennsylvania 16121
Gettysburg, Pennsylvania 17325
Site Public Contact
877-441-7957
Glen Mills, Pennsylvania 19342
Site Public Contact
610-284-8237
Greensburg, Pennsylvania 15601
Site Public Contact
724-838-1900
Greenville, Pennsylvania 16125
Hanover, Pennsylvania 17331
Site Public Contact
717-632-1559
Harrisburg, Pennsylvania 17109
Hazleton, Pennsylvania 18201
Indiana, Pennsylvania 15701
Johnstown, Pennsylvania 15901
Site Public Contact
814-534-4724
Lebanon, Pennsylvania 17042
Lewisburg, Pennsylvania 17837
McKeesport, Pennsylvania 15132
Site Public Contact
412-647-8073
Mechanicsburg, Pennsylvania 17050
Media, Pennsylvania 19063
Monroeville, Pennsylvania 15146
Moon, Pennsylvania 15108
Mount Pleasant, Pennsylvania 15666
N. Huntingdon, Pennsylvania 15642
New Castle, Pennsylvania 16105
Paoli, Pennsylvania 19301
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19107
Philadelphia, Pennsylvania 19111
Site Public Contact
215-728-4790
Philadelphia, Pennsylvania 19114
Philadelphia, Pennsylvania 19140
Site Public Contact
215-728-2983
Phoenixville, Pennsylvania 19460
Site Public Contact
610-983-1800
Pittsburgh, Pennsylvania 15213
Site Public Contact
412-647-2811
Pittsburgh, Pennsylvania 15215
Site Public Contact
412-784-4900
Pittsburgh, Pennsylvania 15219
Site Public Contact
800-533-8762
Pittsburgh, Pennsylvania 15232
Site Public Contact
412-647-8073
Pittsburgh, Pennsylvania 15237
Site Public Contact
412-367-6454
Pittsburgh, Pennsylvania 15243
Site Public Contact
412-502-3920
Pottstown, Pennsylvania 19464
Site Public Contact
610-327-7544
Pottsville, Pennsylvania 17901
Sayre, Pennsylvania 18840
Site Public Contact
800-836-0388
Scranton, Pennsylvania 18510
Seneca, Pennsylvania 16346
Site Public Contact
814-676-7900
Uniontown, Pennsylvania 15401
Upland, Pennsylvania 19013
Washington, Pennsylvania 15301
West Mifflin, Pennsylvania 15122
Site Public Contact
412-653-8100
West Reading, Pennsylvania 19611
Site Public Contact
610-988-9323
Wilkes-Barre, Pennsylvania 18711
Williamsport, Pennsylvania 17701
Site Public Contact
800-598-4282
Williamsport, Pennsylvania 17754
Willow Grove, Pennsylvania 19090
Wynnewood, Pennsylvania 19096
York, Pennsylvania 17403
Site Public Contact
717-741-9229
York, Pennsylvania 17403
Site Public Contact
877-441-7957
York, Pennsylvania 17403
Site Public Contact
877-441-7957
York, Pennsylvania 17408
Site Public Contact
717-724-6760
Providence, Rhode Island 02903
Site Public Contact
401-444-1488
Providence, Rhode Island 02905
Site Public Contact
401-274-1122
Warwick, Rhode Island 02886
Site Public Contact
401-737-7010
Beaufort, South Carolina 29902
Bluffton, South Carolina 29910
Boiling Springs, South Carolina 29316
Site Public Contact
864-241-6251
Charleston, South Carolina 29425
Easley, South Carolina 29640
Gaffney, South Carolina 29341
Georgetown, South Carolina 29440
Greenville, South Carolina 29601
Greenville, South Carolina 29605
Site Public Contact
864-241-6251
Greenville, South Carolina 29605
Site Public Contact
864-241-6251
Greenville, South Carolina 29607
Greenville, South Carolina 29615
Site Public Contact
864-241-6251
Greer, South Carolina 29650
Site Public Contact
864-241-6251
Greer, South Carolina 29651
Hilton Head Island, South Carolina 29926-3827
Seneca, South Carolina 29672
Site Public Contact
864-241-6251
Spartanburg, South Carolina 29303
Union, South Carolina 29379
West Columbia, South Carolina 29169
Aberdeen, South Dakota 57401
Sioux Falls, South Dakota 57104
Sioux Falls, South Dakota 57105
Sioux Falls, South Dakota 57117-5134
Yankton, South Dakota 57078
Alcoa, Tennessee 37701
Collierville, Tennessee 38017
Kingsport, Tennessee 37660
Knoxville, Tennessee 37920
Site Public Contact
865-544-9773
Memphis, Tennessee 38120
Nashville, Tennessee 37204
Site Public Contact
800-811-8480
Amarillo, Texas 79106
Dallas, Texas 75235
Dallas, Texas 75237
Dallas, Texas 75390
Galveston, Texas 77555-0565
Houston, Texas 77030
Houston, Texas 77030
Site Public Contact
713-873-2000
Houston, Texas 77030
Site Public Contact
713-790-2700
Houston, Texas 77030
Houston, Texas 77070
Nassau Bay, Texas 77058
Richardson, Texas 75080
Sugar Land, Texas 77479
Site Public Contact
281-242-2873
The Woodlands, Texas 77385
Bristol, Virginia 24201
Burke, Virginia 22015
Chesapeake, Virginia 23320
Fairfax, Virginia 22031
Fairfax, Virginia 22033
Gloucester, Virginia 23061
Lynchburg, Virginia 24501
McLean, Virginia 22102
Site Public Contact
240-632-4284
Mechanicsville, Virginia 23116
Midlothian, Virginia 23114
Newport News, Virginia 23601
Richmond, Virginia 23226
Richmond, Virginia 23229
Richmond, Virginia 23230
Richmond, Virginia 23235
Richmond, Virginia 23298
South Hill, Virginia 23970
Suffolk, Virginia 23435
Virginia Beach, Virginia 23454
Williamsburg, Virginia 23185
Woodbridge, Virginia 22192
Auburn, Washington 98001
Bremerton, Washington 98310
Edmonds, Washington 98026
Gig Harbor, Washington 98335
Issaquah, Washington 98029
Kennewick, Washington 99336
Puyallup, Washington 98372
Renton, Washington 98055
Seattle, Washington 98122
Spokane, Washington 99204
Spokane, Washington 99218
Tacoma, Washington 98405
Vancouver, Washington 98664
Vancouver, Washington 98684
Vancouver, Washington 98686
Site Public Contact
503-413-2150
Charleston, West Virginia 25304
Site Public Contact
304-388-9944
Huntington, West Virginia 25701
Antigo, Wisconsin 54409
Appleton, Wisconsin 54911
Appleton, Wisconsin 54915
Ashland, Wisconsin 54806
Brookfield, Wisconsin 53045
Burlington, Wisconsin 53105
Chilton, Wisconsin 53014
Eau Claire, Wisconsin 54701
Eau Claire, Wisconsin 54701
Franklin, Wisconsin 53132
Germantown, Wisconsin 53022
Grafton, Wisconsin 53024
Green Bay, Wisconsin 54301
Green Bay, Wisconsin 54303
Green Bay, Wisconsin 54311
Janesville, Wisconsin 53548
Johnson Creek, Wisconsin 53038
Kenosha, Wisconsin 53142
La Crosse, Wisconsin 54601
Madison, Wisconsin 53792
Marinette, Wisconsin 54143
Marshfield, Wisconsin 54449
Medford, Wisconsin 54451
Menomonee Falls, Wisconsin 53051
Site Public Contact
262-257-5100
Mequon, Wisconsin 53097
Milwaukee, Wisconsin 53209
Milwaukee, Wisconsin 53211
Milwaukee, Wisconsin 53215
Milwaukee, Wisconsin 53226
Site Public Contact
414-805-3666
Milwaukee, Wisconsin 53233
Minocqua, Wisconsin 54548
Mukwonago, Wisconsin 53149
Neenah, Wisconsin 54956
Oak Creek, Wisconsin 53154
Site Public Contact
414-805-0505
Oconomowoc, Wisconsin 53066
Site Public Contact
262-928-7878
Oconto Falls, Wisconsin 54154
Oshkosh, Wisconsin 54904
Oshkosh, Wisconsin 54904
Racine, Wisconsin 53405
Racine, Wisconsin 53406
Rhinelander, Wisconsin 54501
Rice Lake, Wisconsin 54868
Sheboygan, Wisconsin 53081
Stevens Point, Wisconsin 54481
Stevens Point, Wisconsin 54482
Sturgeon Bay, Wisconsin 54235-1495
Summit, Wisconsin 53066
Two Rivers, Wisconsin 54241
Waukesha, Wisconsin 53188
Site Public Contact
262-928-7632
Waukesha, Wisconsin 53188
Waupaca, Wisconsin 54981
Wausau, Wisconsin 54401
Site Public Contact
877-405-6866
Wauwatosa, Wisconsin 53226
Wauwatosa, Wisconsin 53226
West Allis, Wisconsin 53227
West Bend, Wisconsin 53095
Site Public Contact
414-805-0505
Weston, Wisconsin 54476
Wisconsin Rapids, Wisconsin 54494
Site Public Contact
715-422-7718
Bayamon, Puerto Rico 00959-5060
Site Public Contact
787-395-7085
Bayamon, Puerto Rico 00961
Site Public Contact
787-780-2865
Manati, Puerto Rico 00674
Site Public Contact
787-621-4397
San Juan, Puerto Rico 00917
Site Public Contact
787-274-3387
San Juan, Puerto Rico 00927
San Juan, Puerto Rico 00936
Site Public Contact
787-763-1296
More Details
- NCT ID
- NCT04457596
- Status
- Recruiting
- Sponsor
- Alliance for Clinical Trials in Oncology
Detailed Description
PRIMARY OBJECTIVE: I. To determine if the invasive disease-free survival (iDFS) with T-DM1 and tucatinib is superior to the iDFS in the control arm (T-DM1 + placebo) when administered to high risk patients with HER2-positive breast cancer and residual disease after neoadjuvant HER2-directed therapy. SECONDARY OBJECTIVES: I. To evaluate whether treatment with tucatinib plus T-DM1 compared to treatment with T-DM1 alone (T-DM1 plus placebo) improves the following: Ia. Breast cancer free survival (BCFS). Ib. Distant recurrence-free survival (DRFS). Ic. Brain metastases-free survival (BMFS). Id. Overall survival (OS). II. To evaluate whether treatment with tucatinib plus T-DM1 compared to treatment with T-DM1 alone (T-DM1 plus placebo) reduces the incidence of brain metastases. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive T-DM1 intravenously (IV) over 30-90 minutes on day 1 and placebo orally (PO) twice daily (BID) on days 1-21. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive T-DM1 IV over 30-90 minutes on day 1 and tucatinib PO BID on days 1-21. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days, then every 6 months for 10 years.